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INTRODUCTION
Osteoarthritis (OA) is the most common form of arthritis and a leading 
cause of disability among the elderly population worldwide. In the 
United States, an estimated 27 million adults had OA in 2005 (ref. 1). 
The prevalence is projected to increase because of OA’s association 
with aging and obesity.2 Typical OA symptoms include pain, swelling, 
and stiffness in joints commonly in hands, knees, hips, or spine. OA 
patients may suffer a reduced quality of life or become disabled as 
the disease progresses. Current treatments for OA are symptomatic 
or palliative, and there is no cure for OA. Patients with severe OA often 
require joint replacement surgery in order to maintain mobility.3
Compelling evidence suggests that interleukin-1 (IL-1), a key 
inflammatory cytokine secreted by chondrocytes and cells within 
the synovium, is an important intra-articular mediator of cartilage 
loss and inflammation during OA development.4 IL-1 increases the 
levels of matrix-degrading enzymes and reduces the synthesis of 
extracellular matrix proteins by chondrocytes.2 Moreover, IL-1 medi-
ates hyperalgesia and pain in the OA joints by acting on the noci-
ceptive system.5 The IL-1 receptor antagonist (IL-1Ra), a physiologic 
inhibitor of IL-1 signaling, holds promise as a biologic treatment for 
OA. Indeed, intra-articular injections of recombinant human IL-1Ra 
are able to protect against the development of experimentally 
induced OA lesions in dogs.6 However, a single, intra-articular injec-
tion of IL-1Ra was not effective in treating OA of the human knee,7 
probably because of the rapid clearance of IL-1Ra from the joint.8
Because OA is a chronic disease, a therapeutic agent such as IL-1Ra 
needs to be present in diseased joints for extended periods of time. 
Intra-articular gene transfer of IL-1Ra cDNA is a promising approach 
to delivering the IL-1Ra protein to the joint for OA treatment. Several 
proof-of-concept studies have achieved promising results in this 
regard. For example, delivery of equine IL-1Ra cDNA via adenoviral 
vector into joints of horses with experimentally induced OA leads to 
elevated intra-articular expression of IL-1Ra protein for 4 weeks and 
also significantly reduces the severity of OA.9 Furthermore, studies 
in which synoviocytes or chondrocytes are transduced in vitro by 
lentiviral or retroviral vectors containing the IL-1Ra cDNA and are 
then transplanted into animal joints with OA also demonstrate 
significant chondroprotective effects.10–12 Ex vivo delivery of IL-1Ra 
cDNA to human rheumatoid joints has also been achieved.13,14
Using recombinant adeno-associated viral (rAAV) vector to trans-
fer IL-1Ra cDNA into joints is more expeditious for clinical application 
because of its safety profile, in vivo delivery, and long-term expression 
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Interleukin-1 (IL-1) plays an important role in the pathophysiology of osteoarthritis (OA), and gene transfer of IL-1 receptor 
antagonist (IL-1Ra) holds promise for OA treatment. A preclinical safety and biodistribution study evaluated a self-complementary 
 adeno-associated viral vector carrying rat IL-1Ra transgene (sc-rAAV2.5rIL-1Ra) at 5 × 108, 5 × 109, or 5 × 1010 vg/knee, or human 
IL-1Ra transgene (sc-rAAV2.5hIL-1Ra) at 5 × 1010 vg/knee, in Wistar rats with mono-iodoacetate (MIA)–induced OA at days 7, 26, 
91, 180, and 364 following intra-articular injection. The MIA-induced OA lesions were consistent with the published data on 
this model. The vector genomes persisted in the injected knees for up to a year with only limited vector leakage to systemic 
circulation and uptake in tissues outside the knee. Low levels of IL-1Ra expression and mitigation of OA lesions were observed 
in the  vector-injected knees, albeit inconsistently. Neutralizing antibodies against the vector capsid developed in a dose-
dependent  manner, but only the human vector induced a small splenic T-cell immune response to the vector capsid. No local or 
 systemic  toxicity attributable to vector administration was identified in the rats as indicated by clinical signs, body weight, feed 
 consumption, clinical pathology, and gross and microscopic pathology through day 364. Taken together, the gene therapy vector 
demonstrated a favorable safety profile.
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potential. Gene transfer using self-complementary rAAV (sc-rAAVIL-
1Ra) produces a therapeutic IL-1Ra level in inflamed rabbit knees.15 
Likewise, AAV-mediated human IL-1Ra (sc-rAAV-hIL-1Ra) transgene 
delivery into horse forelimb joints effectively transduces synovial 
fibroblasts and articular chondrocytes and provides biologically rel-
evant hIL-1Ra expression.16 In vitro transfer using selected serotypes 
of sc-rAAV vector also showed success in both equine and human 
synovial cells.16 Collectively, these preclinical studies consistently 
demonstrate the efficacy of intra-articular IL-1Ra cDNA gene transfer 
for OA treatment.
We performed an investigational new drug–enabling pre-
clinical safety study to evaluate toxicity and biodistribution of 
 sc-rAAV2.5-IL-1Ra in a rat model of OA, to support approval of 
first-in-human trials for the vector in patients with OA. Because the 
human IL-1Ra protein may potentially cause an immune response 
in rats, the study tested three dose levels of the rat IL-1Ra cDNA vec-
tor and one high dose level of the human IL-1Ra cDNA vector that 
would be used in the clinical trial. General toxicity endpoints, includ-
ing clinical signs, clinical pathology, gross and microscopic pathol-
ogy, as well as immunogenicity and biodistribution, were evaluated 
throughout a year after intra-articular vector administration.
ReSUlTS
The study design and group designations are summarized in Table 1, 
and the details are described in the Materials and Methods section. 
The rats, including control animals (group 1), were administered 
mono-iodoacetate (MIA) by intra-articular injection to induce OA 
lesions and 3 days later were intra-articularly administered vehicle 
or vector. The day of vector (or vehicle) injection was designated as 
study day (SD) 1 for each animal.
Evaluation of general toxicity (mortality, clinical signs, body 
and organ weights, and clinical, macroscopic, and microscopic 
pathology)
Five rats from various dose groups (two from group 1, on SD 98 and 
175; one from group 2, on SD 287; and two from group 4, on SD 
79 and SD 271) underwent moribund euthanasia and one rat from 
group 2 was found dead on SD 326. On the basis of macroscopic 
and microscopic examination, none of the moribund euthanasias or 
premature deaths was attributable to the vector dosing.
No vector dose-related adverse clinical signs were observed in 
the rats. Transient signs of abnormal gait, limping, and shaking were 
observed in a few animals, which as expected were consequences 
of the cartilage injury induced by the MIA administration.
Among male and female animals, group mean body weights were 
not statistically different among the vehicle dose group and the 
vector dose groups at any time point. Body weights increased over 
time during the study, and the growth curves of the  vector-treated 
males or females were comparable with their corresponding vehicle 
controls (Figure 1).
Feed consumption data were quite variable. Sporadically, 
mean daily feed consumption was statistically significantly differ-
ent between the vehicle control group and a vector dose group. 
However, there were no clear trends of vector dose-dependent dif-
ferences in males or females (data not shown).
Hematology and clinical chemistry parameters (see 
Supplementary Table S1 for a complete list of parameters) were 
analyzed for the main study animals euthanized at SD 7, 26, 91, 
180, and 364. There were no alterations in hematology or clinical 
chemistry parameters that were attributed to treatment with the 
sc-rAAV2.5rIL-1Ra or sc-rAAV2.5hIL-1Ra vector. While statistically 
significant differences between vehicle control and vector dosed 
groups were identified for a few hematology and clinical chem-
istry parameters, the changes were slight or were without a dose 
response, only identified in one sex, or not consistently identified 
over time (Supplementary Table S2).
Weights of major organs were measured at necropsy for all 
main study animals, and relative organ-to-body weights and 
 organ-to-brain weights were also calculated. Absolute and/or rela-
tive weights of several organs in the vector dose groups were sig-
nificantly different from those in their corresponding control groups 
only at SDs 7, 91, and 180 (i.e., the differences were not observed at 
SDs 26 and 364). In general, the statistically significant organ weight 
changes lacked a dose–response relationship, and/or there was no 
Table 1 Study design
Group Treatment
300 µg MIA  
(right knee)a
Vector doseb (vg/right knee);  
no left knee injection
Number of animals per group (M/F)  
at euthanasia timec
SD 7 SD 26d SD 91 SD 180 SD 364e
1 Vehicle control Yes 0 (vector vehicle) 8/8 8/8 8/8 8/8 8/8
2 Low-dose rat vector Yes 5 × 108 8/8 8/8 8/8 8/8 8/8
3 Mid-dose rat vector Yes 5 × 109 8/8 8/8 8/8 8/8 8/8
4 High-dose rat vector Yes 5 × 1010 8/8 8/8 8/8 8/8 8/8
5 High-dose human vector Yes Human, 5 × 1010 − 8/8 − − −
6 Untreated No No 5/5f − − − −
MIA, mono-iodoacetate.
aGroup 1–5 rats received an injection of MIA in the right knee and of saline in the left knee. bThe day of vector (or vehicle) dosing was designated as study day (SD) 1. 
Rat vector is the vector carrying rat IL-1Ra transgene (i.e., sc-rAAV2.5rIL-1Ra) and human vector is the vector carrying human IL-1Ra transgene (i.e., sc-rAAV2.5hIL-1Ra). 
cFor group 1–5, five of the eight males and eight females per subgroup were designated as the main study animals. The remaining three of each sex (designated as 
satellite animals) were included for assessment of vector concentration and transgene expression in the knee joint. dMales were euthanized at SDs 25 and 26 and 
females at SDs 26 and 27. This euthanasia time point is referred to as SD 26 throughout the text. eSatellite male animals were euthanized at SD 363, and this euthanasia 
time point is referred to as SD 364 throughout the text. fGroup 6 animals received no treatment and euthanasia day was arbitrarily designated as SD 8 for males and 
SD 9 for females.
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consistency between absolute and relative weights or between 
males and females and thus were considered to be incidental 
and not attributable to the vector administration (Supplementary 
Table S3).
Macroscopic examination identified sporadic findings in vari-
ous tissues from the main study rats in various treatment groups 
(Supplementary Table S4). None of the findings were considered to 
have resulted from vector administration. Minimal to mild foci of 
yellow discoloration of the soft tissues in the right knees and red 
discoloration of popliteal lymph nodes were identified in a few ani-
mals in both the control and vector-dosed groups, which were con-
sidered to be a consequence of the MIA-induced lesions.
The primary microscopic finding in the MIA-dosed right knees 
(femorotibial articulation and patella) of both the control and 
 vector-dosed rats was chondrocyte necrosis, along with matrix pro-
teoglycan depletion and synovial mononuclear infiltration, which 
progressed over time to include cartilage fibrillation/fragmenta-
tion, cartilage loss/collapse, subchondral fibrosis, bone formation/
resorption, osteophyte formation, subchondral osteosclerosis, 
and chondrocyte hyperplasia (Figures 2 and 3 and Supplementary 
Table S5). These lesions suggest that OA was successfully induced 
by the MIA administration. The lesions are consistent with pub-
lished data on this model.17,18 Histopathological examination did 
not identify any adverse effects in the right knees attributable to the 
vector administration. There was also no obvious histopathological 
evidence that the rat or human vector treatment resulted in mitiga-
tion of the MIA-induced OA lesions in the right knees.
Minimal-to-mild immune cell infiltrates were identified in the left 
knees (saline-injected), the skin and subcutis around the region of 
the injection site (both the left and right knees), and/or the draining 
popliteal lymph nodes in some rats at early euthanasia time points, 
SD 7 or SD 26. These findings were usually observed both in the con-
trol and vector-dosed animals and considered to be associated with 
injection procedures and/or MIA administration.
Microscopic examination of remaining tissues did not identify 
any lesions associated with MIA or vector administration.
Evaluation of cartilage damage in the knees by Mankin scoring
The knees from group 1 (control) and group 4 (high-dose rat vec-
tor) main study animals euthanized at SD 7, 180, and 364 were 
evaluated by Mankin scoring to quantify MIA-induced cartilaginous 
lesions in the knees. The Mankin score is frequently used for histo-
pathological classification of OA severity, focusing on evaluation 
of cartilage damage, with a scale ranging from 0 (normal cartilage) 
to 14 (worst possible score).19 The Mankin score results confirmed 
that injection of MIA successfully induced cartilage degeneration in 
the right knees of the rats. The Mankin scores increased with time. 
Moreover, the median Mankin score (when combined for males and 
females) of the right knees in the high-dose vector group (group 4) 
was significantly lower than that in the control group (group 1) at 
the SD 7 and SD 180 euthanasia time points, suggesting the vector 
treatment reduced the severity of cartilage damage. However, the 
possible therapeutic effect of the vector was not observed in the 
rats euthanized on SD 364 (Table 2).
Vector pharmacokinetics and biodistribution
Concentrations of vector genome in the blood were below the 
limit of quantitation (50 vg/µg genomic DNA) at 4 hours or 24 
hours  post-vector injection in all the control and low-dose vector 
animals, as well as in mid-dose vector males and some females. 
Some females in the mid-dose vector group (group 3) showed low 
levels of vector in the blood at both time points (group geometric 
mean of 2 vg copies/µg DNA at 4 hours and 13 vg copies/µg DNA 
at 24 hours). Following high-dose vector injection, both male and 
female animals in group 4 had moderate levels of vector genomes 
in the blood. Vector concentrations were higher at 24 hours (group 
geometric mean of 2,122 vg copies/µg DNA for males and 6,581 vg 
copies/µg DNA for females) than at 4 hours postinjection (group 
geometric mean of 43 vg copies/µg DNA for males and 74 vg 
copies/µg DNA for females). The females appeared to have slightly 
more vector leakage into circulation than the males in the same 
dose group (mid or high dose group) at both time points.
Vector genomes persisted in the right knees up to SD 364 follow-
ing intra-articular injection in all of the vector dose groups (Figure 4). 
The amounts of vector in the right knees were, for the most part, 
dose dependent. The vector concentration in the right knees was 
usually highest at the SD 7 or SD 26 time point and then declined 
in most subgroups over time. No quantifiable vector genomes were 
identified in the left knees of the vector-treated animals or in either 
knee of the control animals.
Little systemic distribution of vector occurred following the 
 intra-articular injection. No quantifiable vector genomes were 
detected in blood from SD 7 onwards. Consistent with the vector 
pharmacokinetics results at 4 and 24 hours, no quantifiable amounts 
of vector were identified throughout the study in any tissues out-
side the knee in rats in the low-dose vector group and males in the 
Figure 1 Body weight changes in rats administered vector or vehicle. 
(a) Males. (b) Females. The data are presented as the group means (data 
were combined from all euthanasia time point subgroups). Control: 
vehicle control group (group 1); low: low-dose rat vector group (group 
2); Mid: mid-dose rat vector group (group 3); High: high-dose rat vector 
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mid-dose vector group. For the mid- (females) and high-dose vector 
groups, low amounts of vector were observed only in liver, adrenal 
gland, spleen, bone marrow, or popliteal lymph nodes at SD 7 or SD 
26. By SD 91 and after, vector was not consistently found outside the 
knee in any dose group. Vector distribution pattern in tissues was 
similar between the high-dose rat vector group and the high-dose 
human vector group at SD 26.
Rat and human IL-1Ra protein expression in knees and serum
In the right (MIA-injected) knees of the control animals (group 1), 
rat IL-1Ra protein levels appeared to be lower than those present in 
the corresponding left knees at SDs 7 and 26 in the females and to a 
lower extent at SD 7 in the males. However, there was no apparent 
difference in the rIL-1Ra levels between the right and left knees in 
the control group rats after SD 26. The loss of endogenous IL-1Ra 
protein in the right knees could be attributable to the MIA-induced 
necrosis of chondrocytes (as identified by the histopathological 
evaluation), one of the cells in the joint that produces IL-1Ra.
A trend toward an increase in rIL-1Ra level in the right knee was 
only observed in some female rats at SDs 26, 91, and 364 in the high-
dose vector groups. However, the low number of samples per dose 
group precluded meaningful statistical analyses. Serum  rIL-1Ra levels 
were also measured in rats treated with or without the vector at SDs 
7, 26, and 364. The majority of the samples were below the lower limit 
of quantification (LLOQ) of the assay (391 pg/ml), and there was no 
clear increase in serum rIL-1Ra levels in rats in any vector dose group 
compared with the corresponding control group (data not shown).
Interestingly, human IL-1Ra protein expression was observed in 
the right knees of group 5 rats at SD 26, and the expression was 
more robust in females than males. The hIL-1Ra level in the right 
knees was significantly higher than the corresponding left knees 
in the female rats, indicating that the vector injection resulted in 
transgene expression in the joint (Figure  5a). Consistent with the 
results in the right knees, the serum hIL-1Ra concentrations in the 
 vector-dosed female animals at SD 26 were significantly higher than 
those in the corresponding control females (Figure 5b).
Cellular and humoral immune responses to the vector
The T-cell immune response to vector AAV2.5 capsid protein VP1 
peptide pools (pp) 1, 2, and 3 was assessed using an interferon γ 
(IFN-γ) ELISpot assay in splenocytes from rats euthanized at SD 26 
and SD 180. Overall, all of the responses were very low (below 40 
spots/250,000 splenocytes) and highly variable. The statistical anal-
ysis showed that only splenocytes from group 5 (high-dose human 
vector group) male rats at SD 26 had significantly higher responses 
to pp2 than control rats (Supplementary Figure S1). However, this 
response was extremely low and can likely be considered biologi-
cally negligible because there were no associated findings identi-
fied in the spleens by histopathological examination.
Serum neutralizing anti-AAV2.5 antibody titers increased in a 
vector dose-dependent manner in both male and female animals 
(Figure 6). The antibody titers in mid- and high-dose vector groups 
rose at SD 26 and peaked at SD 91 and then declined slightly at 
the later time points, SD 180 and SD 364. Rats in the high-dose rat 
vector group and in the high-dose human vector group exhibited 
similar anti-capsid antibody titers at SD 26. Animals administered 
the low dose of vector had generally low antibody titers compared 
with the mid- and high-dose vector groups. In general, no apparent 
Figure 2 Chondrocyte necrosis with depletion of proteoglycans 10 days after MIA injection (SD 7). (a and b) Control knee from a control rat; (c and d) 
MIA-injected knee from a control rat. (a and c) Hematoxylin and eosin stain; (b and d) Safranin O Fast Green stain. In panels c and d, the cartilage of the 
medial tibial plateau (between the two lines) and meniscus (asterisk) contain necrotic chondrocytes. In panel d, reduced cartilage staining by Safranin 
O (red) demonstrates decreased proteoglycan content. The inset in panel c is a higher magnification image showing necrotic chondrocytes (arrows) 
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Figure 3 Cartilage loss with sclerosis of underlying subchondral bone 1 year after MIA injection (SD 364). (a and b) Control knee from a control rat; 
(c and d) MIA-injected knee from a control rat. (a and c) Hematoxylin and eosin stain; (b and d) Safranin O Fast Green stain. In the MIA-injected knee, 
the articular cartilage of the medial tibial plateau (between the two lines) and the medial femoral condyle is missing. The meniscus is fragmented, and 
the central portion of the meniscus is missing. The subchondral bone of the medial tibial plateau and femoral condyle is increased in thickness and 
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Table 2 Mankin scores on knees of rats treated with vehicle or high-dose rat vectora
Treatment Sex SD 7 SD 180 SD 364
Left knee (group 1) Saline (MIA vehicle) M 2.8 (2.5–2.8) 2.2 (2.2–2.3) 4.5 (3.9–5.3)
No vector F 3.8 (2.8–4.3) 4.0 (3.5–4.3) 6.0 (3.5–7.3)
C 2.8 (2.6–3.6) 3.5 (2.1–4.0) 5.0 (3.8–6.3)
Left knee (group 4) Saline (MIA vehicle) M 2.3 (1.5–2.3) 3.8 (3.8–3.8) 5.3 (5.0–6.3)
No vector F 2.0 (1.8–2.0) 4.3 (3.5–5.5) 6.0 (4.8–7.0)
C 2.0 (1.6–2.3) 3.8 (3.6–5.2) 5.6 (4.8–6.8)
Right knee (group 1) MIA M 4.0 (3.0–4.3) 10.0 (9.5–14.0)b 13.0 (11.4–13.3)
Vector vehicle F 4.8 (4.0–4.8)b 10.8 (10.5–14.0) 12.5 (11.8–12.5)b
C 4.1 (3.3–4.7) 10.6 (9.6–14.0)b 12.5 (11.8–13.0)b
Right knee (group 4) MIA M 2.0 (1.5–4.3) 5.3 (4.8–5.3) 14.0 (11.3–14.0)
High-dose rat vector F 2.5 (2.5–2.8)c 6.0 (6.0–9.3) 12.3 (11.8–12.5)
C 2.5 (2.0–3.5)c 5.6 (4.9–8.4)c 12.4 (11.6–14.0)
MIA, mono-iodoacetate.
aData are presented as median and interquartile range (i.e., first quartile–third quartile); n = 4–5 for M (males) or F (females) and n = 9–10 for C (combined). Note knees 
from SDs 26 and 91 euthanasia points were not evaluated. bThe median score is significantly different from that of left knee (group 1) for the same gender. cThe median 
score is significantly different from that of right knee (group 1) for the same gender.
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difference in anti-AAV2.5 antibody generation between males and 
females was noted in most dose groups.
DISCUSSION
The primary objectives of the study were to assess the safety and 
biodistribution of an AAV-mediated gene therapy vector carrying 
rat or human IL-1Ra transgene in an MIA-induced model of OA in 
rats. Intra-articular injection of MIA produced knee lesions con-
sistent with previously reported changes in the MIA-induced OA 
model in the rat.17,18 Specifically, after intra-articular MIA injection, 
the rat knees exhibited extensive chondrocyte necrosis and sub-
sequent development and progression of OA. The Mankin scoring 
evaluation, which focuses on articular cartilage, also confirmed 
that injection of MIA successfully induced cartilage damage in the 
right knees of the rats. This suggests that the OA rat model was 
established as intended to assess the safety and biodistribution of 
the IL-1Ra gene therapy.
Administration of the sc-rAAV2.5rIL-1Ra vector (carrying the 
rat IL-1Ra cDNA) by intra-articular injection at the three tested 
doses (5 × 108, 5 × 109, and 5 × 1010 vg/knee) caused no appar-
ent adverse effects locally or systemically in the rats as evaluated 
by clinical observations, body weight, feed consumption, clinical 
pathology, and macroscopic and microscopic pathology through 
SD 364  post-vector dosing. The sc-rAAV2.5hIL-1Ra vector carry-
ing the human IL-1Ra cDNA (the product to be used in the clinic) 
at the high dose of vector (5 × 1010 vg/knee) also did not exhibit 
 vector-associated adverse effects through SD 26 post-vector dosing.
Following the intra-articular injection of the vector, there was 
only limited vector leakage into circulation in the high-dose vector 
animals and minimal leakage in the mid-dose vector females at 4 
Figure 4 Vector concentrations in right knees as a function of administered dose and time. Each symbol represents vector concentration value for each 
animal in the indicated dose group at the indicated time point. n = 3 (n = 2 for high males at SD 180 and control males, low females, and high females 
at SD 364). Note that values below the quantifiable level (the LLOQ was 50 vg/µg DNA) were designated as 0 vg/µg DNA (shown as 1 µg DNA in the log 











































Figure 5 Concentrations of human IL-1Ra protein in (a) knee-capsule extracts (b) and serum at 26 days after administration of vector containing  hIL-
1Ra transgene. In panel a, # indicates a sample off-scale high and arbitrarily set to the highest standard concentration (2,000 pg/ml) before correction 
for total protein concentration; samples below the LLOQ before correction for protein are shown as X. * indicates significantly different from the left 
knee of group 5 females (P < 0.05) using Kruskal–Wallis test with Dunn’s post hoc analysis. Human IL-1Ra levels obtained from two naive rats are also 
included as baselines. In panel b, most values were below the LLOQ of 31.3 pg/ml, indicated as a dashed line. * indicates P < 0.05 versus the female 
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and 24 hours. By SD 7, no quantifiable vector was found in the blood 
of rats in any dose groups. Consistent with the limited leakage iden-
tified in the vector pharmacokinetics analysis, only low levels of vec-
tor genomes were detected outside the knee in several tissues of 
some high-dose vector animals and a few mid-dose vector females 
on SD 7 and SD 26; no quantifiable vector genomes were identified 
in any tissues outside the knee in the mid-dose vector male animals 
and low-dose vector animals on SD 7 and SD 26, or in any dose 
groups by SD 91 and after. The vector pharmacokinetics and bio-
distribution data suggest that there is no potential safety concern 
about extended vector persistence in off-target organs beyond the 
last time point evaluated in this study.
Following intra-articular injection, the vector genome persisted 
up to SD 364 in the right knees in a generally dose-dependent man-
ner. In most vector dose groups, the vector concentration in the 
right knee peaked on SD 7 or SD 26 and then declined at the later 
time points. However, the vector concentrations in the knees var-
ied among time points, particularly in the low-dose vector females. 
Although vector genomes were consistently present in the right 
knees at all the time points, increased rIL-1Ra protein expression 
was not consistently observed in those knees compared to the 
level in the right knees of corresponding control animals. Loss of 
chondrocytes in the right knees after MIA dosing could at least 
partially an explanation for low transgene expression on the basis 
that there might be insufficient host cells for vector transduction. 
Indeed, previous studies showed that AAV vector transduced both 
the chondrocytes and synovial fibroblasts.15,16,20 The lack of consis-
tent, significant rIL-1Ra expression in the right knees may be fur-
ther confounded by individual animal variation, high background 
 rIL-1Ra expression in the knees, small sample size (only three ani-
mals per group), and potential heterogeneity (knee joints along 
with surrounding tissues) of the knee tissues collected for analysis. 
However, following the human vector dose (group 5), increased 
 hIL-1Ra expression in both the right knee and the serum of some 
male and female animals was observed compared to the corre-
sponding left knees and the control animals, respectively, with the 
increase being statistically significant for the female rats. This sug-
gests that the transgene expression does occur in the knee joint. 
The reason that the female rats exhibited better expression of hIL-
1Ra than male rats is unclear. The vector genome concentrations 
in the knee joint were comparable between male and female rats 
on SD26.  Gender-dependent transgene expression was previously 
reported in several AAV-based gene therapies, although, in those 
cases, males showed greater efficacy.21–23 In this study, the intra-
articular injection is considered as a local route of administration, 
and male and females rats received the same vector dose and vol-
ume. It is possible that female rats have smaller knee joint volume 
than male rats and thus their knee cartilage and synovial tissues 
were subjected to greater exposure to vector solution following the 
injection. Indeed, there are significant gender differences in carti-
lage volume and surface area of men and women.24
Significant effects of the vector dosing on the progression of 
 MIA-induced OA in the rats was not obvious from the histopatho-
logical examination on the overall knee joints. However, the Mankin 
scoring, which focuses on the evaluation of the articular cartilage 
of the femoral condyles, indicated that the high-dose vector treat-
ment reduced the severity of cartilage damage in the right knees 
of the rats on SD 7 and SD 180. This possible therapeutic effect 
of the high-dose vector treatment was not observed in the rats 
euthanized on SD 364. The lack of effect at the longest time point 
is likely due to the aggressive OA model used in the study. At SD 
364, OA had reached a maximum Mankin score in nearly all rats. The 
gene therapy slowed the rate of cartilage loss, but did not reduce 
it to zero; by 1 year, the treated knee joints had caught up with the 
untreated, OA knees.
The discrepant findings in efficacious effects between the histo-
pathological examination and the Mankin scoring evaluation may 
be explained by the latter’s focus on the cartilage of the femoral 
condyle, while the former examined the overall knee joint, and it 
included an assessment not only of changes in articular cartilage 
but also changes in the subchondral bone (resorption, new bone 
formation, fibrosis, bone cyst development, and sclerosis), osteo-
phyte formation (the development of bone spurs at the joint 
periphery to help stabilize the joint), and synovial inflammation 
and proliferation. Also, the Mankin scoring was performed consis-
tently for the same section level (at least when both condyles were 
present in the section at that level), whereas the histopathological 
assessment was performed at the level that had the most severe 
lesions (the most severe lesions were usually on the tibial plateaus 
per the Pathologist). Moreover, Mankin scoring only evaluated the 
slides stained with safranin O/fast green (SOFG) for evaluation of 
collagen and proteoglycan, but the histopathology evaluated both 
the hematoxylin and eosin (H&E)- and SOFG-stained slides.
The vector at similar dose range produces therapeutic IL-1Ra lev-
els in the knee joint of horses and rabbits.15,16 However, the obvious 
efficacy of the vector was not observed in the current animal model, 
Figure 6 Anti-AAV2.5 neutralizing antibody titers in rat serum post-vector administration. The results are presented as mean ± SEM of five animals per 
group. Values reported as “<5” were assigned as “0” (shown as 1 in the log scale graph). Naive: group 6; control: group 1; low: group 2; mid: group 3; high: 
group 4; human: group 5. F, female rats; M, male rats.
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which may be attributed to the fast progression of the MIA-induced 
OA model. Proteoglycan synthesis inhibition and IL-1β expres-
sion are maximal in rats at day 2 post-MIA injection, and extensive 
chondrocyte degeneration occurs at day 1 post-intra-articular MIA 
injection; by days 5 and 7 post-MIA injection, chondrocyte necrosis, 
collapse of cartilaginous matrix, loss of cartilage, and subchondral 
bone remodeling have already occurred.17,18,25 Therefore, at the time 
the vector was administered (i.e., 3 days after the MIA injection), it 
is likely that the lesions were already too severe to be reversed by 
the expression of IL-1Ra. In addition, due to extensive chondrocyte 
death, the vector lost the cellular basis for efficient transduction 
and consequent transgene expression within cartilage. However, 
these circumstances may not be an issue in naturally occurring OA 
in humans, where cartilage degeneration is slowly progressive, typi-
cally taking place over the course of months to years.
Anti-AAV2.5 NAb developed in a dose-dependent manner. The 
antibody titers in serum were relatively high at SD 26 and SD 91 and 
then declined at later time points. The reduction in vector genomes 
present in the tissues between SD 26 and SD 91 might be a conse-
quence of the increased Nab titers by SD 26. Evaluation of the cel-
lular immune response to the AAV2.5 capsid revealed no biologically 
significant immunogenicity following the  intra-articular rat or human 
vector administration, in terms of IFN-γ-producing splenocytes in 
response to ex vivo stimulation by the AAV2.5 capsid peptide pools.
In conclusion, the sc-rAAV2.5IL-1Ra vector delivered by 
 intra-articular administration showed a favorable safety profile in the 
MIA-induced OA rats when they were followed up to 364 days. The 
vector genome persisted in the right knees up to a year  post-injection, 
but outside the knees, vector genomes were below the quantifiable 
level by day 91 post-dosing. The data from this study, along with pre-
vious efficacy studies, warrant further clinical development of the 
AAV-based IL-1Ra gene transfer into knees for OA treatment.
MATeRIAlS AND MeTHODS
Animals
Wistar rats (Crl:WI) were purchased from Charles River Laboratories 
(Wilmington, MA). All animal study procedures were approved by the Lovelace 
Respiratory Research Institute (LRRI) Institutional Animal Care and Use 
Committee. The animals were quarantined and housed according to Standard 
Operating Procedures at LRRI consistent with the Office of Laboratory Animal 
Welfare Guide for the Care and Use of Laboratory Animals. The animals were 
11 to 13 weeks old at the time of the initial dosing. After the animals were 
randomized and assigned to the study groups, they were identified by using 
unique alphanumeric numbers encoded in a transponding microchip (Trovan, 
Santa Barbara, CA) placed subcutaneously between the scapulae.
Vector, MIA, and vehicle controls
Rat vector sc-rAAV2.5rIL-1Ra and human vector sc-rAAV2.5hIL-1Ra were pro-
duced using the triple plasmid transfection method in HEK293 cells, puri-
fied, and characterized at the University of North Carolina (UNC) Vector Core. 
The vector is a self-complementary, recombinant AAV, serotype 2.5 con-
taining the coding region of human or rat IL-1Ra under the transcriptional 
control of the human cytomegalovirus (CMV) immediate early promoter. 
Characterization testing for the vector article included sterility, endotoxin, 
identity, purity, infectious titer, and viral particle titer. The vector formula-
tion buffer (phosphate buffer with 2.7 mmol/l potassium chloride and 350 
mmol/l sodium chloride, pH 7.26), also provided by the UNC Vector Core, 
was used as the vehicle control and diluent for the vector.
The MIA was purchased from Sigma-Aldrich (product#57858, St Louis, 
MO). Sterile saline (0.9% sodium chloride, for injection) obtained from 
Hospira (NDC#0409-4888-10, Grand Island, NE) and Nova-Tech (Cat# 510224, 
Rocky Mount, NC) was used as the MIA diluent and vehicle control.
Study design
The MIA-induced OA model was employed in this study for two reasons. 
First, spontaneous OA is extremely uncommon in rats.26 Intra-articular injec-
tion of MIA generates an experimental OA rat model easily, quickly, reliably, 
and synchronously. Second, the MIA model, unlike the majority of induced 
OA animal models,26 does not involve surgery to the knee joint and thus 
maintains the capsule intact to mimic human OA knee capsules.
The study design is summarized in Table 1. The in-life and general toxicity 
endpoints of the study were conducted in compliance with good laboratory 
practice regulations. Following the release of the healthy rats from quar-
antine, the animals were randomized into dosing groups by sex and body 
weight, using Provantis Software (Instem, Staffordshire, UK), with 40 M/40 
F in each group of groups 1–4, 8 M/8 F in group 5, and 5 M/5 F in group 6. 
Animals in groups 1–4 were further divided into subgroups (8 M/8 F per sub-
group) by scheduled euthanasia time points. In each subgroup, 5 M/5 F rats 
were designated as the main study animals and the other 3 M/3 F as satel-
lite animals to provide knee and lymph node tissues for IL-1Ra and vector 
biodistribution analyses. Each animal in dose groups 1–5 were administered 
MIA (300 μg/knee) in their right knee and saline in their left knee. The MIA 
dose was selected based on data obtained in a pilot study that was designed 
to confirm the MIA model of OA in the Wistar rats. Three days after MIA dos-
ing (SD 4), vector (groups 2–5) or vehicle (group 1) was administered to the 
right knees at the vector doses specified for each dose group in Table 1. The 
three vector doses tested in this study, in terms of the volume of the knee 
joint, are equivalent to the medium, high, and 10× high proposed clinical 
doses. These were based on the doses previously found effective in rabbits 
and horses.15,16 The day an animal received the vector (or vehicle) was desig-
nated SD 1 for that animal. The injection volume was 50 μl per knee for both 
the MIA and vector dosing.
Subgroups of group 1–4 rats were euthanized at SDs 7, 26, 91, 180, and 
364, and the group 5 animals were euthanized at SD 26. In addition, group 
6 animals receiving no treatment (naive) were euthanized at SD 8 (males) 
and SD 9 (females) time point and served as negative controls for the IL-1Ra 
measurements.
Following vector dosing, detailed clinical observations and body weight 
measurements were performed weekly for 13 weeks and thereafter monthly 
for all surviving animals. Feed consumption was collected weekly for 4 
weeks and then monthly. In addition, blood was collected at 4–5 hours and 
24 ± 1 hours post-vector dosing from the SD 180 euthanasia subgroups for 
determination of vector concentration.
The main study rats were euthanized at the scheduled time points by 
i.p. injection of an overdose of a pentobarbital-based euthanasia solution, 
Euthasol. Blood was collected by cardiac puncture into EDTA tubes for vec-
tor biodistribution and hematology analyses (Supplementary Table S1). 
Additional blood was collected and processed to serum for serum chemistry 
tests (Supplementary Table S1), as well as IL-1Ra level and antibodies to the 
AAV2.5 vector capsid. After a complete gross examination, the organs were 
weighed, and tissues were collected for analysis of vector biodistribution, 
IFN-γ EliSpot (splenocytes on SD 26 and SD 180), and microscopic histopa-
thology as assigned in Supplementary Table S6. In addition, the knees and 
popliteal lymph nodes were collected from the satellite study animals for 
analysis of vector genome content, and the knee tissues and sera were also 
collected for IL-1Ra protein assay.
Microscopic histopathology
All fixed tissues (~40 tissues per animal, Supplementary Table S6) from the 
control (group 1), high-dose rat vector (group 4), and high-dose human vec-
tor (group 5) animals were evaluated. Gross lesions from the group 2 and 3 
rats were also processed for histological examination. Because the high-dose 
vector treatment (group 4) did not demonstrate any efficacy or toxicity, only 
the knee joints and draining (popliteal) lymph nodes from the group 2 and 
3 animals at SD 7, 91, and 364 were assessed by microscopic histopathology.
All fixed tissues, except for the knees and patellas, were trimmed, 
 paraffin-embedded, sectioned at ~5 µm, and stained with H&E using stan-
dard histological procedures. The knees and patellas were decalcified in 
EDTA Versenate Decal Solution (Cat# DCVERGAL, American MasterTech, 
Lodi, CA). The patellas were trimmed along their longitudinal axis and sec-
tioned to permit evaluation of the articular surface and subchondral bone. 
The knees were trimmed into two approximately equal halves through a 
frontal plane, and the caudal half was embedded with the cut plane fac-
ing down. The resulting microscopic sections generally included medial 
and lateral femoral condyles, tibial plateaus, and menisci. Four sections of 
knees were cut from each paraffin block at each of two levels, separated by 
~180–220 µm. At each level, one section was stained with H&E, and a second 
section was stained with SOFG to evaluate the collagen and proteoglycans. 
The entire femorotibial joint was evaluated microscopically from sections at 
each level, and the section with the most severe findings was graded. The 
H&E and SOFG slides were evaluated by a board-certified Pathologist. The 
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histopathology evaluation was semi-quantitative, and each gradable find-
ing was assigned into a severity score of 1–4.
Mankin scoring on femoral articular cartilages
Knee joint slides (one level) stained with SOFG from the control (group 1) 
and high-dose rat vector (group 4) main study animals euthanized at SD 
7, 180, and 364 were evaluated using Mankin Score System as previously 
described.19 The Mankin scale ranges from 0 (normal cartilage) to 14 (worst 
possible score). Both femoral condyles on each knee were scored separately 
to determine the final score by two independent reviewers in a blinded 
manner. The average score of both reviewers was used for data analysis.
Quantitation of vector genomes in blood and tissues
Samples of blood, brain, kidneys, heart, gonads (ovaries or testes), adrenal 
glands, lungs, spleen, bone marrow (femur), and liver were collected at nec-
ropsy from each main study animal at all time points for vector biodistribu-
tion analysis. The vector quantity was first analyzed in all tissues (and blood) 
listed above for groups 1 and 4 at SD 7. Tissues from a subgroup were not 
analyzed if no quantifiable vector amount was detected in the same type of 
tissue from the higher vector dose or earlier euthanasia time point. In addi-
tion, the knee joints and popliteal (draining) lymph nodes collected from the 
satellite group animals at all euthanasia time points were assayed for vector 
concentration.
Blood and tissue samples were aliquoted and stored at −80 ± 10 °C until 
the time of DNA extraction. Genomic DNA extraction from blood or tissues 
was performed using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, 
MD) according to manufacturer’s instructions. The sample DNA concentra-
tion was evaluated by measuring the absorbance at 260 nm (A260) and the 
DNA quality by a ratio of A260/A280 using a BioTek µQuant plate reader.
The vector genome copy numbers were assayed by qPCR using a 
Stratagene Mx 3005P System. The assay was a SYBR Green-based real-time 
PCR assay15 performed using a QuantiTect SYBR Green PCR Kit (Qiagen).
The primers used were: forward-CACGCTGTTTTGACCATAGAAGACAC; 
reverse-TTCTTTGATTTGCACCACCGGATCC. The qPCR reaction was per-
formed under the following thermal cycling conditions: 95 °C for 15 min-
utes; 40 cycles of 95 °C for 15 seconds, 60 °C for 30 seconds and 72 °C for 30 
seconds; and 10 minutes at 72 °C for extension, followed by a melting curve 
analysis.
Prior to being used for study sample analysis, the qPCR assay was vali-
dated at LRRI for accuracy, precision, specificity, LLOQ, standard curve, and 
sample stability. Tissues analyzed using 0.5 µg DNA per reaction included 
liver, adrenal gland, brain, heart, testis/kidney, ovary, spleen, and bone mar-
row. The LLOQ of the assay was determined to be 35 vg/µg genomic DNA 
using 0.5 µg of genomic DNA per reaction. Tissues analyzed using 0.1 µg 
DNA per reaction were knee, popliteal lymph nodes, lungs, and blood. The 
LLOQ was determined to be 50 vg/µg genomic DNA using 0.1 µg of genomic 
DNA per reaction.
Analysis of human and rat IL-1Ra protein level in knee joints and 
serum
Rat and human IL-1Ra protein expression was measured in the knee joints 
of the satellite animals. Knee tissues were collected at necropsy and stored 
frozen at −80 ± 10 °C. Upon analysis, each frozen knee tissue sample was 
weighed and then homogenized using a “Tissuemizer” (Tekmar, Mason, 
OH) in Dulbecco’s phosphate-buffered saline (Cat # D8537, Sigma-Aldrich) 
containing 0.1% Triton X-100 (Cat. # T8787, Sigma-Aldrich) and a cocktail of 
proteinase inhibitors (Cat. # P8340, Sigma-Aldrich). Rat IL-1Ra expression 
was analyzed in groups 1–4 at all the time points, and human IL-1Ra was 
analyzed in group 5 at SD 26. The serum rat and human IL-1Ra levels were 
determined in both the main and satellite animals. The IL-1Ra content was 
analyzed using commercially purchased ELISA kits according to standard 
procedures developed based on the manufacturer’s instructions. The rat 
IL-1Ra assay used a modification of the DuoSet kit for mouse IL-1Ra (Cat# 
DY480, R&D Systems, Minneapolis, MN) with rat IL-1Ra used to prepare the 
standard curves. The human IL-1Ra assay used a DRA00B ELISA kit (R&D 
Systems). The ELISA assays for both rat IL-1Ra and human IL-1Ra were quali-
fied prior to being used for study sample analysis at LRRI. The LLOQ for the 
rat IL-1Ra assay was 391 pg/ml and for the human IL-1Ra protein assay was 
31.3 pg/ml. The IL-1Ra protein levels in the knee joints were normalized to 
the total protein content (Pierce Coomassie Protein Assay Kit, Thermo Fisher) 
of the homogenates.
IFN-γ ELISpot analysis of splenocytes
T-cell responses to the vector capsid were analyzed using splenocytes 
obtained from rats euthanized on SD 26 and SD 180. At necropsy, a portion 
of the spleen was collected and used to prepare single cell suspensions. The 
splenocyte suspensions were frozen in freezing media (90% fetal bovine 
serum/10% dimethylsulfoxide) at −80 ± 10 °C and then transferred to a liq-
uid nitrogen cryogenic freezer for storage until ELISpot analysis.
The IFN-γ ELISpot assays were performed using a commercial assay kit (Cat# 
3220-2H, Mabtech, Mariemont, OH) according to the manufacturer’s instruc-
tions. Three peptide pools (i.e., pp1, 2, and 3) of 80–110 peptides each were 
designed as 15-mers offset by five amino acids and spanning the AAV2.5 capsid 
protein VP1 (736 amino acids). The peptides were synthesized by ProImmune 
(Sarasota, FL). The spleen cells (2.5 × 105 viable cells) were stimulated with pp1, 
pp2, or pp3, and the IFN-γ–producing cells were detected and counted on an 
Immunospot plate reader (ImmunoSpot S5 Macro Analyzer with ImmunoSpot 
Software from Cellular Technology, Shaker Heights, OH). Each cell sample 
was run in duplicate. Along with peptide pool stimulation, a subset of cell 
samples were also stimulated with cell culture media (media control stimu-
lus), dimethyl sulfoxide (diluent control stimulus), or concanavalin A (positive 
mitogenic stimulus). In addition, on each day of analysis, negative control cells 
(naive rat splenocytes) and positive control cells (splenocytes collected from 
rats administered 5 × 1010 vg of the rat vector sc-rAAV2.5rIL-1Ra by i.m. injec-
tion on day 42 post-injection) were also included for quality control purposes.
Titration of anti-AAV2.5 NAb in serum
The sera collected at necropsy from group 1–5 main study rats and group 
6 rats were assayed for NAb to the AAV2.5 vector at the University of 
Pennsylvania Immunology Core. The assay was validated prior to sample 
analysis. The serum samples were heat-inactivated at 56 °C for 35 minutes. 
Recombinant AAV2.5.CMV.LacZ (109 genome copies/well, University of 
Pennsylvania Vector Core) was diluted in serum-free Dulbecco’s Modified 
Eagle medium (Corning Cellgro, Tewksbury, MA) and incubated with two-
fold serial dilutions (starting at 1:5) of heat-inactivated serum samples in 
Dulbecco’s Modified Eagle medium for 1 hour at 37 °C. Subsequently, the 
serum–vector mixtures were added to 96-well plates seeded with Huh7 cells 
at 1 × 105 cells/well that had been infected with wild-type human adeno-
virus type 5 (wtHAdV5, 45 particles/cell) 2 hours earlier. After 1 hour, each 
well was supplemented with an equal volume of 20% fetal bovine serum 
(Thermo Fisher Scientific, Waltham, MA) in Dulbecco’s Modified Eagle 
medium and incubated for 18–22 hours at 37 °C and 5% CO2. Then, the cells 
were washed twice in PBS (Corning Cellgro, Tewksbury, MA) and lysed. The 
lysate was developed with mammalian β-Galactosidase Assay Kit for biolu-
minescence according to the manufacturer’s protocol (Applied Biosystems, 
CA) and measured in a microplate luminometer (Clarity, BioTek). The NAb 
titer was reported as the highest serum dilution that inhibited AAV2.5.CMV.
LacZ transduction (β-gal expression) by 50% or more as compared with the 
mouse serum control (Sigma, Allentown, PA).
Statistical analysis
The analyses of the feed consumption, terminal body weight, and organ 
weight data were performed using the Tables & Statistics module of the 
Provantis software (the statistics are SAS software-based). One-way analysis 
of variance (ANOVA) was used to compare the vehicle control and vector 
dose groups, and if significant, Dunnett’s test was used to compare each vec-
tor dose group to the vehicle control.
The statistical analyses of the clinical pathology and in-life body weight 
data were performed using one-way ANOVA to assess treatment effects 
and two-way ANOVA (treatment, time, treatment  ×  time) to assess treat-
ment effects across time. If the ANOVA (one- or two-way) indicated signifi-
cant difference among dose groups, Dunnett’s multiple comparison test 
was applied to assess differences between each vector-dosed group and 
the vehicle control group. The analyses were performed using the SAS soft-
ware system, version 9.2 (Cary, NC). Statistical analyses of the ELISA data and 
ELISpot data were performed using GraphPad Prism (La Jolla, CA). T-test (for 
two groups), one-way ANOVA (for treatment effects more than two groups), 
and two-way ANOVA (for treatment and stimuli effects for ELISpot data) 
analyses were performed as appropriate for the data. All statistical signifi-
cance was assessed at P ≤ 0.05.
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